Denali Therapeutics Reports Third-Quarter 2026 Financial Results
Denali said AVLAYAH net product revenue accelerated to $17.8 million in its second full quarter.
Story updates
09:01:34 PM UTC
SquawkNews
Denali Therapeutics 3Q EPS 37c >DNLI
09:06:19 PM UTC
SquawkNews
*-- Earnings Flash (DNLI) Denali Therapeutics Inc. Reports Q3 Revenue $17.8M, vs.
09:07:17 PM UTC
SquawkNews
Denali Therapeutics kehrt im dritten Quartal 2026 mit 70.1 Millionen US-Dollar in die Gewinnzone zur
09:07:23 PM UTC
SquawkNews
*-- GUIDANCE: (DNLI) Denali Therapeutics Inc. Expects Q4 Revenue Range $30.0M - $32.0M
09:10:30 PM UTC
SquawkNews
Denali reported Q3 2026 net product revenue of $17.8M and net income of $70.1M, including a one-time $194.0M gain on a Priority Review Voucher sale. Cash, cash equivalents and marketable securities totaled approximately $1.0B.Material DetailsContext by AI AnalystThis is an early commercial-stage up…